ArticlePloS one2026
An improved formulation of human neural stem cells for the treatment of geographic atrophy.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThis study aimed to compare the neuroprotective effects of subretinally delivered human central nervous system stem cells (HuCNS-SC) and a novel, single-cell suspension formulation, Neubright (NB) in the RCS rat.
methodsAt postnatal day 21, RCS rats were subretinally injected with a 150,000 cell dose of either HuCNS-SC or NB in a 2 μL volume. The contralateral control eye was injected with balanced salt solution. Visual function outcomes were measured using optokinetic tracking and electroretinography. Whole globes were harvested at P60 and P180 for immunofluorescence (IF). To identify cells in the subretinal space, retinal cross-sections were stained with a human specific marker (STEM121). Cell spread, outer nuclear layer (ONL) thickness, and cell migration were quantified using confocal microscopy and image J.
resultsIF demonstrated a clear presence of STEM121-positive cells in the subretinal space after delivery of both HuCNS-SC and NB. The ONL was thicker in areas adjacent to the injected cells, whereas a greater degree of degeneration was observed outside of treated areas. The novel NB formulation had significantly increased cell spread and visual performance compared to the original HuCNS-SC formulation.
conclusionsA novel single-cell suspension of human neural stem cells, NB, with high cell viability was successfully generated. NB improved cell spread in the subretinal space compared to HuCNS-SC improving visual outcomes in the RCS rat. Translational Relevance: This bridging study will be used as an investigational new drug approval enabling study to evaluate NB in clinical trials for macular retinal degeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.